Opinion|Videos|January 17, 2025
Sequencing Considerations in Relapsed/Refractory CLL
Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment options in the relapsed/refractory setting.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What sequencing considerations influence your choice of upfront therapy for chronic lymphocytic leukemia (CLL), and how do these decisions shape the selection of treatments in the relapsed/refractoryCLL setting?
- How does the treatment sequencing study in CLL/SLL by Rhodes and colleagues, presented at the 2024 American Society of Hematology annual meeting, influence your clinical approach?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
2
INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD
3
AI Reshaping Diabetes Care From Nutrition to Clinical Decisions
4
Contributor: How to Pair Data With Clinical Care to Manage Health Care Costs
5